全文获取类型
收费全文 | 857篇 |
免费 | 33篇 |
国内免费 | 9篇 |
专业分类
耳鼻咽喉 | 2篇 |
儿科学 | 49篇 |
妇产科学 | 23篇 |
基础医学 | 84篇 |
口腔科学 | 15篇 |
临床医学 | 138篇 |
内科学 | 186篇 |
皮肤病学 | 13篇 |
神经病学 | 44篇 |
特种医学 | 75篇 |
外科学 | 46篇 |
综合类 | 13篇 |
预防医学 | 62篇 |
眼科学 | 4篇 |
药学 | 94篇 |
中国医学 | 12篇 |
肿瘤学 | 39篇 |
出版年
2022年 | 16篇 |
2021年 | 30篇 |
2020年 | 9篇 |
2019年 | 25篇 |
2018年 | 19篇 |
2017年 | 14篇 |
2016年 | 16篇 |
2015年 | 20篇 |
2014年 | 21篇 |
2013年 | 31篇 |
2012年 | 46篇 |
2011年 | 31篇 |
2010年 | 34篇 |
2009年 | 36篇 |
2008年 | 24篇 |
2007年 | 39篇 |
2006年 | 34篇 |
2005年 | 45篇 |
2004年 | 24篇 |
2003年 | 35篇 |
2002年 | 18篇 |
2001年 | 16篇 |
2000年 | 15篇 |
1999年 | 10篇 |
1998年 | 21篇 |
1997年 | 19篇 |
1996年 | 23篇 |
1995年 | 17篇 |
1994年 | 12篇 |
1993年 | 8篇 |
1991年 | 11篇 |
1990年 | 11篇 |
1989年 | 12篇 |
1988年 | 15篇 |
1987年 | 11篇 |
1986年 | 16篇 |
1985年 | 7篇 |
1984年 | 11篇 |
1983年 | 9篇 |
1982年 | 7篇 |
1981年 | 5篇 |
1980年 | 10篇 |
1979年 | 6篇 |
1978年 | 6篇 |
1977年 | 7篇 |
1976年 | 10篇 |
1975年 | 4篇 |
1974年 | 5篇 |
1970年 | 4篇 |
1967年 | 3篇 |
排序方式: 共有899条查询结果,搜索用时 15 毫秒
91.
The primary care physician can accurately diagnose hand injuries by obtaining a thorough patient history and performing a complete physical examination of the hand. When the severity of injury is doubtful, immobilization in a splint with next-day referral is appropriate. Immediate consultation should be obtained with nerve or vascular damage, fracture-dislocation injuries, open fractures, substantial skin loss, or flexor tendon injuries at or distal to the wrist. 相似文献
92.
93.
Longer‐term follow‐up and outcome by tumour cell proliferation rate (Ki‐67) in patients with relapsed/refractory mantle cell lymphoma treated with lenalidomide on MCL‐001(EMERGE) pivotal trial
下载免费PDF全文
![点击此处可从《British journal of haematology》网站下载免费的PDF全文](/ch/ext_images/free.gif)
Andre Goy Sevgi Kalayoglu Besisik Johannes Drach Radhakrishnan Ramchandren Michael J. Robertson Irit Avivi Jacob M. Rowe Raoul Herbrecht Achiel Van Hoof Lei Zhang Sherri Cicero Tommy Fu Thomas Witzig 《British journal of haematology》2015,170(4):496-503
Patients with mantle cell lymphoma (MCL) generally respond to first‐line immunochemotherapy, but often show chemoresistance upon subsequent relapses, with poor outcome. Several studies of the immunomodulator, lenalidomide, have demonstrated its activity in MCL including the MCL‐001 study in relapsed/refractory patients who had failed defined prior therapies of anthracyclines or mitoxantrone, cyclophosphamide, rituximab and also bortezomib. We present here the long‐term efficacy follow‐up of the prospective phase II MCL‐001 study (N = 134), including new exploratory analyses with baseline Ki‐67 (MIB1), a biological marker of tumour proliferation. With longer follow‐up, lenalidomide showed a 28% overall response rate [ORR; 8% complete response (CR)/CR unconfirmed (CRu)]. Median duration of response (DOR), progression‐free survival and overall survival were 16·6, 4·0 and 20·9 months, respectively. Myelosuppression continued to be the most common grade 3/4 toxicity. Several studies of MCL patients treated with chemotherapy, rituximab and bortezomib have shown an inverse association between survival and Ki‐67. Ki‐67 data in 81/134 MCL‐001 patients showed similar ORRs in both low (<30% or <50%) versus high (≥30% or ≥50%) Ki‐67–expressing groups, yet lower Ki‐67 levels demonstrated superior CR/CRu, DOR and survival outcomes. Overall, lenalidomide showed durable efficacy with a consistent safety profile in heavily pretreated, relapsed/refractory MCL post‐bortezomib. 相似文献
94.
95.
Anoop Rehal Zsófia Benkő Catalina De Paco Matallana Argyro Syngelaki Deepa Janga Simona Cicero Ranjit Akolekar Mandeep Singh Petya Chaveeva Jorge Burgos Francisca S. Molina Makrina Savvidou Maria De La Calle Nicola Persico Maria Soledad Quezada Rojas Ashis Sau Elena Greco Neil O’Gorman Kypros H. Nicolaides 《American journal of obstetrics and gynecology》2021,224(1):86.e1-86.e19
96.
97.
CM Olsen AC Green RE Neale PM Webb RA Cicero LM Jackman SM O'Brien SL Perry BA Ranieri DC Whiteman;for the QSkin Study 《International journal of epidemiology》2012,41(4):929-929i
The QSkin Sun and Health Study comprises a cohort of 43 794 men and women aged 40-69 years randomly sampled from the population of Queensland, Australia in 2011. The cohort was established to study the development of skin cancer and melanoma in the population with the highest reported incidence of these diseases in the world. At baseline, besides demographic items and general medical history, information about standard pigmentary characteristics (including hair and eye colour, freckling tendency, tanning ability and propensity to sunburn), past and recent history of sun exposure and sunburns, sun protection behaviours, use of tanning beds and history of skin cancer was collected by self-completed questionnaire. Participants have given their consent for data linkage to the universal national health insurance scheme and for linkage to cancer registries and pathology databases, thus ensuring complete ascertainment of all future skin cancer and melanoma occurrences and medical treatments and other cancer events. Linkage to these registers will occur at predetermined intervals. Approval to access QSkin data can be obtained on application to the study investigators and submission of a formal research plan that has previous approval from the human research ethics committee of the applicant's institution. 相似文献
98.
Thiazolidinedione effects on blood pressure in diabetic patients with metabolic syndrome treated with glimepiride. 总被引:4,自引:0,他引:4
Giuseppe Derosa Arrigo Francesco Giuseppe Cicero Angela Dangelo Antonio Gaddi Pietro Dario Ragonesi Mario Nello Piccinni Sibilla Salvadeo Leonardina Ciccarelli Fabio Pricolo Morena Ghelfi Ilaria Ferrari Lorenza Montagna Roberto Fogari 《Hypertension research》2005,28(11):917-924
The aim of our study was to compare the long-term effect of pioglitazone and rosiglitazone on blood pressure control of diabetic patients with metabolic syndrome treated with glimepiride. We evaluated 91 type 2 diabetic patients with metabolic syndrome. All were required to have been diagnosed as diabetic for at least 6 months, and to have failed to achieve glycemic control by dietary changes and the maximum tolerated dose of the oral hypoglycemic agents sulfonylureas or metformin. All patients took a fixed dose of 4 mg/day glimepiride. We administered pioglitazone (15 mg/day) or rosiglitazone (4 mg/day) for 12 months in a randomized, double-blind fashion, and evaluated body mass index (BMI), glycemic control, blood pressure and heart rate (HR) throughout the treatment period. A total of 87 patients completed the study and were randomized to receive double-blind treatment with pioglitazone or rosiglitazone. An increase in BMI was observed after 12 months (p < 0.05) in both groups. After 9 and 12 months, there were significant decreases in glycated hemoglobin (HbA(1c)), mean fasting plasma glucose (FPG), postprandial plasma glucose (PPG), fasting plasma insulin (FPI), and postprandial plasma insulin (PPI) in both treatment groups (p < 0.05 at 9 months and p < 0.01 at 12 months for all parameters). Furthermore, homeostasis model assessment index (HOMA index) improvement was obtained at 9 and 12 months (p < 0.05 and p < 0.01, respectively) in both groups. Significant systolic blood pressure (SBP) and diastolic blood pressure (DBP) improvement (p < 0.05, respectively) was observed in both groups after 12 months. There were no significant changes in transaminases at any point during the study. We can conclude that the association of a thiazolinedione to the glimepiride treatment of type 2 diabetic subjects with metabolic syndrome is associated to a significant improvement in the long-term blood pressure control, related to a reduction in insulin-resistance. 相似文献
99.
Monocyte-mediated antibody-dependent cell-mediated cytotoxicity: the role of the metabolic burst 总被引:4,自引:0,他引:4
Human monocytes respond to opsonized microorganisms with a "metabolic burst" composed of an increase in oxygen consumption, an increase in hexose monophosphate shunt (HMPS) activity, and the generation of reactive oxygen species (ROS). We investigated the role of the metabolic burst in antibody-dependent cell-mediated cytotoxicity (ADCC) by human monocytes toward anti-D coated erythrocyte target cells because recent studies suggested a role for oxygen-dependent bactericidal mechanisms in ADCC. In normal monocytes, we found that ADCC was nearly halved under hypoxic conditions. Several agents known to impair activation of the burst, such as vincristine, cation chelators, and a sulfhydryl reagent, all decreased cytotoxicity if added before initiation of contact between target and effector cells. Cytotoxicity was inhibited by 2-deoxyglucose but not fluoride, suggesting a nonglycolytic role for glucose in ADCC, perhaps in the HMPS pathway. Although these data suggested a role for the metabolic burst in ADCC, scavengers of ROS did not impair cytotoxicity, and monocytes from chronic granulomatous disease (CGD) patients who had a defective metabolic burst had normal levels of ADCC. We conclude that ADCC toward anti-D coated erythrocyte target cells was the result of at least two independent but closely related cytotoxic pathways. Although one of these pathways appeared to involve the metabolic burst, the potentially cytotoxic reactive oxygen species did not appear to play a role in this system. 相似文献
100.